Research & Development
Moderna's COVID-19 booster vaccine recommended by US CDC Advisory Committee on Immunization Practices
22 November 2021 -

Biotechnology company Moderna Inc (Nasdaq:MRNA) announced on Friday that the use of the booster dose of the Moderna COVID-19 vaccine at 50 µg dose level for people aged 18 and older has been recommended by US Food and Drug Administration's (FDA) Emergency Use Authorization (EUA).

The Moderna Inc booster approval follows a vote by the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP). The positive vote was unanimous with 11 ACIP members recommending the booster.

Concurrently, the ACIP recommendation follows the US FDA's emergency use authorization of a booster dose. This ACIP recommendation will be forwarded to the Director of the CDC and the US Department of Health and Human Services (HHS) for review and adoption.

In addition, the ACIP, which is comprised of independent health experts, advises the CDC on the populations and circumstances for which vaccines should be used.